December 21, 2001 - 3:55 p.m.
OSI Pharmaceuticals and Gilead Sciences Announce Closing of Oncology Assets Deal
Printer Friendly Version 
November 28, 2001 - 3:41 p.m.
Gilead Begins Phase I Study of GS7904L, an Investigational Anticancer Drug
Printer Friendly Version 
November 26, 2001 - 3:34 p.m.
OSI Pharmaceuticals Acquires Oncology Assets from Gilead Sciences
Printer Friendly Version 
November 13, 2001 - 3:33 p.m.
Gilead Begins Phase I Study of GS7836, an Investigational Anticancer Drug
Printer Friendly Version 
November 13, 2001 - 3:29 p.m.
Gilead Announces Data from Studies of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic Hepatitis B Virus Infection
Printer Friendly Version 
November 12, 2001 - 3:24 p.m.
Gilead Announces Data from Studies of Adefovir Dipivoxil Demonstrating Significant Improved Liver Function and Viral Load Reduction in Patients with Chronic Hepatitis B Virus Infection
Printer Friendly Version 
November 09, 2001 - 3:05 p.m.
Gilead Announces Primary Endpoint Met in Phase III Study of Adefovir Dipivoxil 10 mg in Patients with Lamivudine-Resistant Chronic Hepatitis B Infection
Printer Friendly Version 
October 26, 2001 - 3:03 p.m.
U.S. FDA Approves Gilead Sciences’ Anti-HIV Drug Viread™
Printer Friendly Version 
October 25, 2001 - 2:53 p.m.
Gilead Sciences Announces Third Quarter 2001 Financial Results
Printer Friendly Version 
October 25, 2001 - 2:51 p.m.
Gayle Edlund Wilson Joins Gilead Sciences Board of Directors
Printer Friendly Version 
October 23, 2001 - 2:47 p.m.
Gilead Licenses Rights Under Its Selex and Aptamer Patent Estate to Archemix
Printer Friendly Version 
October 18, 2001 - 2:34 p.m.
European CPMP Gives Positive Opinion on Viread™, Gilead’s New Once-Daily Treatment for HIV Infection
Printer Friendly Version 
October 03, 2001 - 2:26 p.m.
Gilead Announces FDA Advisory Committee Supports Use of Viread™ in Treatment-Experienced Patients with HIV Infection
Printer Friendly Version 
October 02, 2001 - 2:25 p.m.
FDA Posts Background Documents for October 3 Viread™ Advisory Committee Meeting
Printer Friendly Version 
September 25, 2001 - 1:23 p.m.
Gilead’s Investigational Antiretroviral Agent Viread™ Reduces Viral Load in HIV Patients with Resistant Virus in Pivotal Phase III Study
Printer Friendly Version 
September 19, 2001 - 1:21 p.m.
Gilead Sciences Announces Results From Phase III Study of Adefovir Dipivoxil In Precore Mutant Chronic Hepatitis B Virus Infection
Printer Friendly Version 
September 06, 2001 - 1:20 p.m.
Gilead Sciences Announces Acceptance of Late Breaker Abstract at Upcoming ICAAC Meeting
Printer Friendly Version 
August 22, 2001 - 1:08 p.m.
Gilead Sciences Announces Degussa Corporation Will Acquire Gilead's 49 Percent Interest in Proligo L.L.C.
Printer Friendly Version 
August 21, 2001 - 1:03 p.m.
Gilead’s Viread™ for the Treatment of HIV Infection to be Reviewed by FDA Antiviral Advisory Committee on October 3, 2001
Printer Friendly Version 
July 26, 2001 - 12:58 p.m.
Gilead Sciences Announces Second Quarter 2001 Financial Results
Printer Friendly Version 
June 22, 2001 - 12:53 p.m.
Gilead Achieves Primary Endpoint in Phase III Study of Adefovir Dipivoxil for Chronic Hepatitis B Virus Infection
Printer Friendly Version 
June 11, 2001 - 12:46 p.m.
Gilead Sciences Initiates Phase I Study in China of Adefovir Dipivoxil, Investigational Compound for the Treatment of Chronic Hepatitis B Infection
Printer Friendly Version 
June 05, 2001 - 12:44 p.m.
Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV
Printer Friendly Version 
May 04, 2001 - 12:41 p.m.
Gilead Sciences Submits Marketing Authorisation Application to European Regulatory Authorities for Tenofovir DF for the Treatment of HIV Infection
Printer Friendly Version 
May 01, 2001 - 12:36 p.m.
Gilead Sciences Submits New Drug Application to U.S. FDA for Tenofovir DF for the Treatment of HIV Infection
Printer Friendly Version 
April 26, 2001 - 12:23 p.m.
Gilead Sciences Announces First Quarter 2001 Financial Results
Printer Friendly Version 
April 24, 2001 - 12:01 p.m.
Gilead Sciences Broadens Entry Criteria for Tenofovir DF Expanded Access Program in the United States
Printer Friendly Version 
April 23, 2001 - 11:48 a.m.
Gilead Sciences Announces Data from Studies of Adefovir Dipivoxil, Investigational Agent for the Treatment of Chronic Hepatitis B Infection
Printer Friendly Version 
April 18, 2001 - 11:36 a.m.
Cordell W. Hull Joins Gilead Sciences Board of Directors
Printer Friendly Version 
February 27, 2001 - 11:32 a.m.
Roche Submits Oral Flu Drug Tamiflu for Regulatory Approval in Europe
Printer Friendly Version 
February 20, 2001 - 11:28 a.m.
Gilead Sciences Announces Preliminary Results from Phase III Study of Investigational Anti-HIV Agent Tenofovir DF
Printer Friendly Version 
February 14, 2001 - 11:15 a.m.
JAMA Study Reveals Roche's Tamiflu™ Effective In Protecting People Exposed to Influenza
Printer Friendly Version 
February 02, 2001 - 11:12 a.m.
Gilead Sciences Stockholders Clear the Way for 2-for-1 Stock Split
Printer Friendly Version 
January 31, 2001 - 11:26 a.m.
Gilead Announces Start of Early Access Program for Investigational Anti-HIV Agent Tenofovir DF in United States and France
Printer Friendly Version 
January 25, 2001 - 10:53 a.m.
Gilead Sciences Announces Fourth Quarter and Year End 2000 Financial Results
Printer Friendly Version 
January 22, 2001 - 10:44 a.m.
Gilead Board of Directors Appoints James M. Denny as Chairman
Printer Friendly Version 
January 19, 2001 - 9:01 a.m.
Gilead Sciences to Release Fourth Quarter and Year-End 2000 Earnings on Thursday, January 25, 2001
Printer Friendly Version 
January 19, 2001 - 8:59 a.m.
Gilead Board of Directors Approves Two-For-One Stock Split
Printer Friendly Version 
January 18, 2001 - 8:48 a.m.
Pharmacy Shelves Make Room for Tamiflu™ Liquid for Kids
Printer Friendly Version 
January 16, 2001 - 8:42 a.m.
Gilead Sciences and GlaxoSmithKline Modify Terms of License Agreement for NX 211, Gilead's Investigational Compound for the Treatment of Cancer
Printer Friendly Version 
January 07, 2001 - 8:25 a.m.
Cubist Pharmaceuticals and Gilead Sciences Announce European Commercialization Agreement for Investigational Antibacterial Agent Cidecin™
Printer Friendly Version 
NASDAQ (US Dollar)
$74.19
 Stock is Up 0.45 (0.61%)
Data as of 07/26/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote